At Px, we put Patient Experience at the heart of delivering better oncology outcomes. Using OWise, its freely available and clinically-validated cancer patient support app platform, Px applies a patient-powered approach to conduct nationwide, community-driven Real World Evidence studies. OWise impacts value-based cancer care by: • Bridging the evidence gap by supporting health organizations with patient-powered Real-World Insights. • Supporting patients with personalized support. • Enabling patients to share health data in real-time with their care teams. As the annual cost of cancer exceeds $1.16 trillion today, we need to address the individual and financial burdens by increasing patients’ wellbeing and significantly improving clinical outcomes while saving health care costs. The award-winning mobile app ‘OWise breast cancer’ has been independently studied, showing that 90% of the patients and 90% of the treating clinicians recommend OWise to cancer patients. OWise is designed to support patients as part of their everyday life during treatment. OWise has been selected by the NHS Innovation Accelerator (2015) to fast-track adoption, it was listed in the Top25 of all health apps (IQVIA, 2017) and has won numerous prizes and awards since (see https://owise.uk/our-science). Px applies advanced data-analytics to the anonymised, real-world patient-reported outcome (PRO) data providing real-time feedback to patients designed to improve both quality of life and overall survival. On a population scale, insights into the PRO data, which are commercialised to health care providers and payers, are aimed at improving both cancer outcomes and cost-effectiveness globally. With our main product OWise, we have developed the best-in-class mobile app to support cancer patients during treatment. OWise is now recognised as the key, patient-driven cancer support platform that combines improving • patient experience, • clinical outcomes, and • cost-effectiveness.